Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD).

Autor: Tilburt JC; Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota.; Division of General Internal Medicine, Mayo Clinic, Scottsdale, Arizona.; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota., Zahrieh D; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Pacyna JE; Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota., Petereit DG; Rapid City Regional Cancer Care Institute, Monument Health, Rapid City, South Dakota., Kaur JS; Department of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida., Rapkin BD; Department of Epidemiology and Population Health, Division of Community Collaboration and Implementation Science, Albert Einstein College of Medicine, Bronx, New York., Grubb RL 3rd; Department of Urology, Medical University of South Carolina, Charleston, South Carolina., Chang GJ; Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Morris MJ; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York., Kovac EZ; Department of Urology, Rutgers New Jersey Medical School, Newark, New Jersey., Babaian KN; Department of Surgery, Southern Illinois University, Springfield, Illinois., Sloan JA; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Basch EM; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina., Peil ES; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Dueck AC; Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, Arizona., Novotny PJ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Paskett ED; Ohio State University College of Medicine, The Ohio State University, Columbus, Ohio., Buckner JC; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Joyce DD; Department of Urology, Mayo Clinic, Rochester, Minnesota., Montori VM; Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota., Frosch DL; Palo Alto Medical Foundation Research Institute, Palo Alto, California., Volk RJ; Division of Cancer Prevention and Population Sciences, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kim SP; Division of Urology, Anschutz Medical Center, University of Colorado, Aurora, Colorado.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2022 Mar 15; Vol. 128 (6), pp. 1242-1251. Date of Electronic Publication: 2021 Dec 10.
DOI: 10.1002/cncr.34062
Abstrakt: Background: Decision aids (DAs) can improve knowledge for prostate cancer treatment. However, the relative effects of DAs delivered within the clinical encounter and in more diverse patient populations are unknown. A multicenter cluster randomized controlled trial with a 2×2 factorial design was performed to test the effectiveness of within-visit and previsit DAs for localized prostate cancer, and minority men were oversampled.
Methods: The interventions were delivered in urology practices affiliated with the NCI Community Oncology Research Program Alliance Research Base. The primary outcome was prostate cancer knowledge (percent correct on a 12-item measure) assessed immediately after a urology consultation.
Results: Four sites administered the previsit DA (39 patients), 4 sites administered the within-visit DA (44 patients), 3 sites administered both previsit and within-visit DAs (25 patients), and 4 sites provided usual care (50 patients). The median percent correct in prostate cancer knowledge, based on the postvisit knowledge assessment after the intervention delivery, was as follows: 75% for the pre+within-visit DA study arm, 67% for the previsit DA only arm, 58% for the within-visit DA only arm, and 58% for the usual-care arm. Neither the previsit DA nor the within-visit DA had a significant impact on patient knowledge of prostate cancer treatments at the prespecified 2.5% significance level (P = .132 and P = .977, respectively).
Conclusions: DAs for localized prostate cancer treatment provided at 2 different points in the care continuum in a trial that oversampled minority men did not confer measurable gains in prostate cancer knowledge.
(© 2021 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: